FNDC5 and sarcopenia: Despite irisin's proposed protective role against obesity and sarcopenia, our findings suggest that greater 3‐year increases in irisin were associated with increased odds of obesity, abdominal obesity, sarcopenia and sarcopenic obesity at the follow‐up.